TSH ≥30 mU/L may not be necessary for successful 131I remnant ablation in patients with differentiated thyroid cancer

Purpose To determine whether thyroid-stimulating hormone level ≥ 30 mU/L is necessary for radioiodine (131I) remnant ablation (RRA) in patients with differentiated thyroid cancer (DTC), as well as its influencing factors and predictors. Methods A total of 487 DTC patients were retrospectively enroll...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European thyroid journal 2023-08, Vol.12 (4), p.1-11
Hauptverfasser:	Ju, Nianting, Hou, Liying, Song, Hongjun, Qiu, Zhongling, Wang, Yang, Sun, Zhenkui, Luo, Quanyong, Shen, Chentian
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - surgery Apolipoproteins Cholesterol differentiated thyroid cancer Humans Iodine Radioisotopes radioiodine therapy Retrospective Studies thyroglobulin Thyroid Neoplasms thyroid remnant ablation thyroid-stimulating hormone Thyroidectomy Thyrotropin
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Purpose To determine whether thyroid-stimulating hormone level ≥ 30 mU/L is necessary for radioiodine (131I) remnant ablation (RRA) in patients with differentiated thyroid cancer (DTC), as well as its influencing factors and predictors. Methods A total of 487 DTC patients were retrospectively enrolled in this study. They were divided into two groups (TSH < 30 and ≥ 30 mU/L) and further divided into eight subgroups (0–
ISSN:	2235-0802 2235-0640 2235-0802
DOI:	10.1530/ETJ-22-0219